Therapeutic drug monitoring of tacrolimus in pancreas transplantation at São Lucas Hospital

• Autor(a) principal: Oliveira,Luciana Mello de
• Data de Publicação: 2007
• Outros Autores: Bender,Ana Lígia, Traesel,Moacir A., Kroth,Leonardo, Hartmann,Marcelo J., Gullo Neto,Salvador, Saitovitch,David, Thiesen,Flavia Valladão
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Jornal Brasileiro de Patologia e Medicina Laboratorial (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1676-24442007000500006
• topic: Tacrolimus; Immunosuppression; Pancreas transplantation; Therapeutic drug monitoring; Transplantation

Tacrolimus (FK 506), a potent immunosuppressive drug used in prevention and treatment of rejection of transplanted organs, exhibits efficacy related to its blood levels and has a narrow therapeutic index. These factors require frequent monitoring of patients blood levels, in attempt to adjust the dose to reach the best drug concentration with minimum side effects. In this historic study, the authors evaluated tacrolimus blood profile in patients submitted to pancreas transplantation between June 2002 and March 2004. The results show that blood levels were, mostly, within subtherapeutic (39.1%) and toxic (43.4%) ranges. Considering post-transplantation period, subtherapeutic levels were more frequent until three months after the graft receiving (51.1%) and between three and six months (41.9%), whereas toxic levels were more common six months after the transplantation (63%). Patients who received pancreas/kidney transplantation showed a tendency to present toxic levels. The same did not happen with the patients who received isolated pancreas and pancreas after kidney; these patients presented subtherapeutic blood levels in all post-transplantation periods. The results found in this study reassure the importance of therapeutic monitoring to achieve the adequate blood levels of tacrolimus following pancreas transplantation.